Browse studies, page 1092
Page 1092 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial program American heart journal, 2024
- Sodium-glucose cotransporter 2 inhibitors-but not insulin-enhance renal branched-chain amino acid catabolism Frontiers in endocrinology, 2025
- Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025
- Effects of sodium-glucose co-transporter 2 inhibitors on ultrafiltration in patients with peritoneal dialysis: a protocol for a randomized, double-blind, placebo-controlled, crossover trial (EMPOWERED) Clinical and experimental nephrology, 2024
- Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis European journal of heart failure, 2024
- SGL-TX-MR-study protocol acute effects of SGLT2 inhibitor on kidney allograft oxygen tension, a randomized, double-blind, placebo controlled crossover trial Trials, 2025
- Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design ESC heart failure, 2024
- Novel Versus Conventional Sequencing of β-Blockers, Sodium/Glucose Cotransportor 2 Inhibitors, Angiotensin Receptor-Neprilysin Inhibitors, and Mineralocorticoid Receptor Antagonists in Stable Patients With Heart Failure With Reduced Ejection Fraction (NovCon Sequencing Study): Protocol for a Randomized Controlled Trial JMIR research protocols, 2025
- Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial BMJ open respiratory research, 2026
- A multicenter, open-label, single-arm trial of the long-term safety of empagliflozin treatment for refractory diabetes mellitus with insulin resistance (EMPIRE-02) Journal of diabetes investigation, 2024
- Effects and safety of dapagliflozin in paediatric hereditary kidney disease: protocol for a multicentric, prospective, open and randomised crossover study (DAPA-PedHKD) BMJ open, 2025
- Empagliflozin to prevent post-operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery: Rationale and design of the EMPOAF trial Pacing and clinical electrophysiology : PACE, 2024
- Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025
- Impact of empagliflozin on cardiac structure and function assessed by echocardiography after myocardial infarction: a post-hoc sub-analysis of the emmy trial Clinical research in cardiology : official journal of the German Cardiac Society, 2025
- The Steno 1 study: Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes-rationale and protocol of the prospective, randomized, open-labelled multicentre study Diabetes, obesity & metabolism, 2025
- Delivering guideline-directed medical therapy for heart failure with reduced ejection fraction as an over-encapsulated polypill: rationale and protocol for the COMBO-HF-X pilot crossover randomised clinical trial BMJ open, 2025
- Dapagliflozin reduces epicardial adipose tissue in patients with heart failure and type 2 diabetes Diabetes, obesity & metabolism, 2025
- Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025
- Short-term renal and cardiac outcomes of combined ARNI and SGLT2 therapy in AHF patients: a prospective single-arm interventional study Frontiers in cardiovascular medicine, 2026
- Assessing the Sympatholytic Effects of SGLT2 Inhibitors in Anuric Haemodialysis Patients Using Microneurography: Study Protocol for a Mechanistic Proof-of-Concept Trial Kidney & blood pressure research, 2024
- Randomized investigation of heart failure therapy in patients with advanced cancer at risk of cardiac wasting: Rationale and design of the EMPATICC trial European journal of heart failure, 2025
- Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLE. Journal of clinical lipidology, 2025
- Empagliflozin in patients with autosomal dominant polycystic kidney disease (EMPA-PKD): study protocol for a randomised controlled trial BMJ open, 2024
- Digital implementation strategy to increase SGLT2 inhibitor uptake in heart failure: Study design of EMAIL-HF ESC heart failure, 2025
- The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction Cardiovascular diabetology, 2025
- SGLT2 inhibitors reduce the salt sensitivity of blood pressure in type 2 diabetes via enhanced postprandial natriuresis Cardiovascular diabetology, 2026
- The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025
- Effect of Empagliflozin on Serum Ferritin and Its Relationship With Inflammatory Markers in Prediabetic and Diabetic Patients Journal of diabetes research, 2025
- Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter - 2 inhibitors for Sleep Apnea (ADIPOSA) study Contemporary clinical trials, 2025
- Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase BMJ open, 2025
- Potential Therapeutic Effects of Empagliflozin Through Elevated Plasma Citrulline Levels in Heart Failure With Preserved Ejection Fraction Circulation journal : official journal of the Japanese Circulation Society, 2025
- Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study BMJ open, 2026
- Safety and Short-Term Effects of Empagliflozin in Patients with Heart Failure and End-Stage Renal Disease American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026
- Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin Compared With Empagliflozin Journal of cardiovascular pharmacology, 2025
- Design and rationale of the EMPagliflozin after Aortic Valve Replacement (EMPAVR) study: A randomized clinical trial American heart journal, 2026
- Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study Trials, 2026
- Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study Drug design, development and therapy, 2026
- A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial Nature communications, 2026
- Evaluation of the efficacy of empagliflozin in patients with preserved left ventricular ejection fraction undergoing transcatheter aortic valve implantation for aortic stenosis: protocol for a randomised, open-label, controlled study BMJ open, 2026
- Newly Diagnosed Atrial Fibrillation After Transient Ischemic Attack Versus Minor Ischemic Stroke in the POINT Trial Journal of the American Heart Association, 2021
- Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes Diabetes care, 2017
- First-Time Usage of SGLT2 Inhibitors in Patients With Type 2 Diabetes Who Are Fasting Ramadan: Efficacy and Safety Journal of diabetes research, 2025
- SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function Clinical journal of the American Society of Nephrology : CJASN, 2022
- Hemodynamic Determinants of Activity Measured by Accelerometer in Patients With Stable Heart Failure JACC. Heart failure, 2021
- Cardiovascular outcomes with canagliflozin - is it on the CANVAS? Expert opinion on pharmacotherapy, 2018
- Effect of empagliflosin on renal filtration in patients with coronary heart disease undergoing percutaneous coronary intervention Kardiologiia, 2020
- Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes Diabetes, 2016
- Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations Scientific reports, 2017
- Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial American journal of kidney diseases : the official journal of the National Kidney Foundation, 2022
- Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions European journal of heart failure, 2022
- Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study Diabetes, obesity & metabolism, 2023
- Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure ESC heart failure, 2021
- Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes Basic & clinical pharmacology & toxicology, 2024
- Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial Circulation, 2022
- Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial The lancet. Diabetes & endocrinology, 2021
- Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. Diabetes, obesity & metabolism, 2020
- Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial JACC. Heart failure, 2021
- Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial Cardiovascular diabetology, 2020
- Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction Journal of the American College of Cardiology, 2022
- How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial Cardiovascular diabetology, 2019
- Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers Advances in therapy, 2012
- SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial Diabetes, 2021
- Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers Clinical therapeutics, 2015
- Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β. Cell metabolism, 2020
- Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial BMC cardiovascular disorders, 2023
- Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study PloS one, 2022
- Comparative analysis of the addition of empagliflozin versus doubling the furosemide dose in decompensated heart failure Cardiovascular drugs and therapy, 2025
- Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial Journal of cardiac failure, 2023
- Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction Circulation, 2022
- Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes European heart journal. Cardiovascular pharmacotherapy, 2020
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial European heart journal, 2021
- Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis Diabetes, obesity & metabolism, 2024
- To investigate the effect of a high-fat diet on pharmacokinetics/renal function/RAAS-related parameters after a single dose of empagliflozin in healthy Chinese adults BMC pharmacology & toxicology, 2026
- Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study Clinical therapeutics, 2015
- Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial BMJ open, 2017
- Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial Diabetes care, 2023
- SGLT2 Inhibitors in Older Adults with Heart Failure with Preserved Ejection Fraction Drugs & aging, 2022
- Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease Nuclear medicine communications, 2021
- Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor Drug research, 2018
- Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure ESC heart failure, 2020
- Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials Journal of diabetes and its complications, 2016
- Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial Diabetes, obesity & metabolism, 2022
- Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes Diabetes technology & therapeutics, 2022
- Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial Diabetes, obesity & metabolism, 2023
- #4534 finerenone added to RAS/SGLT2 blockade for NON-diabetic chronic kidney disease: results of a preclinical double-blinded randomized controlled trial Nephrology, Dialysis and Transplantation, 2023
- Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial Diabetes Care, 2019
- OR27-6 Effects of the SGLT2-Inhibitor Empagliflozin in Patients With Chronic Syndrome of Inadequate Antidiuresis (SIAD) - Results of a Double-Blind, Randomized, Placebo-Controlled, Crossover Trial Journal of the Endocrine Society, 2022
- Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial American Society of Nephrology. Clinical Journal, 2020
- 1719-P: Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 25 mg in Patients with Type 2 Diabetes: A 24-Week Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with 28-Week Open-Label Extension Diabetes, 2026
- Efficacy and Safety of Fixed-Dose Combination of Empagliflozin-Sitagliptin-Metformin ER versus Dapagliflozin-Sitagliptin-Metformin ER in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: A Phase III Randomized Double-Blind Trial Journal of Diabetology, 2026
- OR25-08 Brain-Derived Neurotrophic Factor levels (BDNF) in Hyponatremia Correction -Subanalysis of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial Journal of the Endocrine Society, 2025
- Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial BMC Gastroenterology, 2023
- Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial Cardiovascular Diabetology, 2021
- Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice Journal of the American Society of Nephrology, 2023
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial Cardiovascular Diabetology, 2015
- Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial Diabetes Care, 2021
- Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine Cardiovascular Diabetology, 2021
- Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial Beni-Suef University Journal of Basic and Applied Sciences, 2023
- Linagliptin as add‐on to empagliflozin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two‐part, randomized, placebo‐controlled trial Diabetes, obesity and metabolism, 2018
- The effect of empagliflozin on right ventricular function in heart failure patients with reduced ejection fraction: analysis from the randomized empire hf clinical trial European Heart Journal, 2024
